Extrait du spectacle de Michèle Bernier “Même pas une ride”.
- Tous nos posts tagués cancer du sein et mammographie.
- Notre playlist de vidéos ironiques (parodies, squetches) sur le milieu médical.
Le Sketch sur la Mammographie vue par Michèle Bernier
Extrait du spectacle de Michèle Bernier “Même pas une ride”.
Seeking safe solutions, by Dr Carolyn Dean
Dr. Carolyn Dean’s book outlines the statistics and issues within several categories of prescription drugs that have caused deaths despite being properly prescribed and used.
Death by Modern Medicine: Seeking Safe Solutions, goes beyond the statistics of deaths due to drugs to how the medical monopoly that created the system in the first place is allowed to control health care. There are chapters on propaganda, health care bureaucracy, the business of cancer, media and our own personal addictions to sugar and drugs, and the denial we all harbor to help us cope with the overwhelming burden, are woven into this 380 page volume.
Read Prescription drug abuse may now be the top cause of accidental death in America, NaturalNews, 18 Dec 2013
The Untold Story of Psychotropic Drugging
Video by derekw6826’s channel published on 13 Dec 2010.
Prenatal Exposure to Bisphenol A at Environmentally Relevant Doses Adversely Affects the Murine Female Reproductive Tract Later in Life
Exposure to endocrine-disrupting chemicals during critical developmental periods causes adverse consequences later in life; an example is prenatal exposure to the pharmaceutical diethylstilbestrol (DES). Bisphenol A (BPA), an environmental estrogen used in the synthesis of plastics, is of concern because its chemical structure resembles that of DES, and it is a “high-volume production” chemical with widespread human exposure.
In this study we investigated whether prenatal BPA causes long-term adverse effects in female reproductive tissues in an experimental animal model previously shown useful in studying effects of prenatal DES.
Timed pregnant CD-1 mice were treated on days 9-16 of gestation with BPA (0.1, 1, 10, 100, or 1,000 mug/kg/day). After delivery, pups were held for 18 months; reproductive tissues were then evaluated.
Ovarian cysts were significantly increased in the 1-mug/kg BPA group; ovarian cyst-adenomas were seen in the other three BPA-treated groups but not in corn-oil controls. We observed increased progressive proliferative lesions of the oviduct after BPA treatment, similar to those described in response to DES. Further, although not statistically different from the controls, prominent mesonephric (Wolffian) remnants and squamous metaplasia of the uterus, as well as vaginal adenosis, were present in BPA-treated mice, similar to lesions reported following DES treatment. More severe pathologies observed in some BPA-treated animals included atypical hyperplasia and stromal polyps of the uterus; sarcoma of the uterine cervix; and mammary adenocarcinoma. We did not observe these lesions in controls.
These data suggest that BPA causes long-term adverse reproductive and carcinogenic effects if exposure occurs during critical periods of differentiation.
The number of UK women under aged 50 diagnosed with breast cancer has topped 10,000 for the first time
DES Daughters are 82% more likely to develop breast cancer after age 40 … Could the fact that Breast cancer in women under 50 is becoming more common be explained by the fact that the majority of DES Daughters are only reaching their 40’s now?
Children with autism often take multiple drugs, despite limited evidence about the drugs’ long-term safety
Children with autism often take multiple drugs, despite limited evidence about the drugs’ long-term safety…
The objectives of this study were to examine rates and predictors of psychotropic use and multiclass polypharmacy among commercially insured children with autism spectrum disorders (ASD).
This retrospective observational study used administrative medical and pharmacy claims data linked with health plan enrollment and sociodemographic information from 2001 to 2009. Children with ASD were identified by using a validated ASD case algorithm. Psychotropic polypharmacy was defined as concurrent medication fills across ≥ 2 classes for at least 30 days. Multinomial logistic regression was used to model 5 categories of psychotropic use and multiclass polypharmacy.
Among 33,565 children with ASD, 64% had a filled prescription for at least 1 psychotropic medication, 35% had evidence of psychotropic polypharmacy (≥ 2 classes), and 15% used medications from ≥ 3 classes concurrently. Among children with polypharmacy, the median length of polypharmacy was 346 days. Older children, those who had a psychiatrist visit, and those with evidence of co-occurring conditions (seizures, attention-deficit disorders, anxiety, bipolar disorder, or depression) had higher odds of psychotropic use and/or polypharmacy.
Despite minimal evidence of the effectiveness or appropriateness of multidrug treatment of ASD, psychotropic medications are commonly used, singly and in combination, for ASD and its co-occurring conditions. Our results indicate the need to develop standards of care around the prescription of psychotropic medications to children with ASD.
administrative claims, autism spectrum disorder, commercially insured, psychotropic polypharmacy
Celia McBride: “My internet research found that in the UK, only 20 babies had been born to women from their own frozen eggs up to December 2012”
” I am sitting in a clinic in Spain. The waiting room encircles a cubed glass courtyard housing four colossal circular cacti covered in fur, like ova under a microscope. The walls are hung with contemporary art. All the canvases feature babies: gurgling smiles, downy hair, chubby wrists. Female staff in pencil skirts slink past, clipboards in hand. The leather banquettes are lined with straight and lesbian couples, mainly in their late 30s and 40s, chatting sotto voce in Spanish, German and Italian. I am the only woman here on my own. I am waiting to have my fertility tested. ”
Continue reading ‘I’m so glad I’ve frozen my eggs’
by Celia McBride, The Guardian, 14 Dec 2013
More about DES studies on fertility and pregnancy.
Side Effects of BPA Exposure by Body Unburdened
This BPA infographic is provided by Body Unburdened aiming to help you live a happy and healthy life by providing informative articles, nutritious and delicious recipes, and all-natural & easy-peasy DIYs.
Possble risk of cervical or vaginal cancer higher in women previously treated for pre-cancerous cells on cervix
Although the risk of cervical cancer after treatment for screen detected cervical precancer is low compared with non-treated women, the incidence of invasive cervical cancer is still significantly higher than in the general population. These findings are confirmed by Strander and colleagues in a trend analysis that linked data from pathology, cancer, and cause of death registries that have covered the whole Swedish population for more than half a century. The authors report that the risk of developing or dying from cervical or vaginal cancer in women with a history of treatment for CIN3 (cervical intraepithelial neoplasia grade 3) is two to three times higher than in the general population. Furthermore the increase in risk among women treated for CIN3 rises significantly with older age and more recent year of treatment.
These results agree with previous data suggesting that the rates of residual or recurrent high grade CIN after treatment are higher for older than for younger women. Endocervical precancerous lesions, a predisposing factor for recurrence, are more common in older women than in younger ones. The lower recurrence rates in younger women that are independent of the completeness of excision suggest that age specific immunity may also contribute to the ultimate cure of cervical precancer.
It is worrying that Strander and colleagues found that women who received local treatment more recently were at greater risk of developing cervical and vaginal cancer. The authors suggest that the use of less aggressive treatments in the two most recent decades may have adversely affected oncological outcomes. The trend in treatment was driven by an increasing awareness that extensive procedures are associated with poor reproductive outcomes. Recent meta-analyses of reports published since the end of the 1970s and registry based cohort studies have shown that pregnant women with a history of excisional treatment of CIN have a greater risk of premature delivery, particularly if the excised cones were large. Researchers from Norway have also described a parallel trend between less aggressive treatment for cervical precancer and a lower risk of preterm delivery.
The study population comprising more than three million women years of follow-up after treatment gave the current trend analysis enough power to identify significant differences between different subgroups of women. (Nevertheless, an age-period interaction term was not included in the log-linear model and this could have informed readers about the age specificity of the period effect.) Further analysis of the Swedish data on compliance with follow-up could provide important information on the possible reasons for treatment failure. The suggestion of reduced therapeutic effectiveness over time might also be partly explained by the decreased use of hysterectomy over the past two decades. A separate analysis of cervical and vaginal cancer rates, adjusted for rates of hysterectomy and for trends in the dimensions of excised cones, would help interpret the observed period effect.
Research is needed to identify accurate biomarkers that predict a woman’s future risk of cancer. A recent review concluded that testing for DNA from human papilloma virus helps to identify early treatment failure (recurrence within two years of treatment for cervical precancer), with higher sensitivity and similar specificity to follow-up cytology or histological assessment of the section margins. However, longer term data are limited. A cohort study from the Netherlands assessed the predictive value of combined cytological and virological follow-up for 10 years after treatment for cervical precancer. The overall cumulative incidence of recurrent CIN2 or worse was 17%, and that for CIN3 or worse was 9%. In women with two negative tests (cytology and high risk human papillomavirus DNA) at six and 24 months post-treatment, the risk of these outcomes was similar to that in women who tested negative for cervical precancer at baseline screening. Further cohort studies with long term follow-up are needed to confirm these results and to generate more evidence on the safety of different follow-up protocols for women treated for cervical precancer.
Currently, colposcopists who treat women with high grade CIN lesions must choose between complete excision to obtain free margins or a more prudent approach, especially if a further pregnancy is desired. Published and aggregated data still leave considerable room for doubt about the magnitude of the association between the extent of treatment and risk of later preterm delivery. Divergent findings may be explained by variability in therapeutic practices, particularly the size of the cone excised. The COSPCC study—a meta-analysis of individual patient data—should allow more precise measurement of the obstetric and oncological safety associated with different treatment options, while accounting for patient and lesion characteristics. The study should also provide more detailed evidence on how to balance treatment decisions.
However, Strander and colleagues’ study makes it clear that women who have been treated for a high grade intraepithelial cervical lesion, particularly those aged 50 years or more, require careful surveillance, and that measures should be taken to assure full compliance with follow-up. The data also underline the need for better standardisation and quality assurance in colposcopic practice to achieve an optimal balance between risk of cancer and obstetric safety.
Sylvie, Fille Distilbène, “confiante” attend le délibéré
Sylvie Le Cossec, l’auteure de Distilbène, Mon Fils n’aura Jamais son Bac, une Sarthoise mère d’un enfant polyhandicapé qui demandait ce jeudi au tribunal de Nanterre de condamner UCB Pharma, le laboratoire qui a commercialisé le Distilbène prescrit à sa mère, estimait, au sortir de l’audience, que “le lien de causalité mère-fille devrait aboutir à la condamnation d’UCB Pharma”. En revanche, pour son fils, elle a demandé au TGI une contre-expertise, qui pourrait entraîner de nouvelles années de procédure. Le juge annoncera sa décision le 6 mars.
Lisez “Fille Distilbène”. Sylvie Le Cossec “confiante” attend le délibéré, le Télégramme, 16 janvier 2014